Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Omid Hamid

Showing results (21-30 of 188) with videos related to

Pageof 19
Sort By:
Journal of Surgical Oncology|October 28, 2015
Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanomaDevin C Flaherty, Brianna W Hoffner, Briana J Lau, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 27, 2018
Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?Constantin A Dasanu, Yazeed Samara, Ion Codreanu, et al.
Cancer Immunology, Immunotherapy : CII|March 3, 2012
Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumabVafa Shahabi, Gena Whitney, Omid Hamid, et al.
American Journal of Clinical Oncology|January 24, 2015
Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanomaLynn E Spitler, Peter Boasberg, Steven O'Day, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2012
Sunitinib therapy for melanoma patients with KIT mutationsDavid R Minor, Mohammed Kashani-Sabet, Maria Garrido, et al.
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Programmed death 1 immune checkpoint inhibitorsMeghna S Trivedi, Brianna Hoffner, Jennifer L Winkelmann, et al.
Journal of Translational Medicine|April 19, 2018
The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017Paolo A Ascierto, Corrado Caracò, Jeffrey E Gershenwald, et al.
Frontiers in Medicine|December 26, 2022
Case report: Later onset of NRAS-mutant metastatic melanoma in a patient with a partially-excised giant congenital melanocytic nevusBruno Almeida Costa, Victor Zibara, Vasundhara Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk diseaseOmid Hamid, Jolie C Solomon, Ronald Scotland, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanomaJeffrey S Weber, Omid Hamid, Scott D Chasalow, et al.
Pageof 19

Showing results (21-30 of 188) with videos related to

Sort By:
Pageof 19
Journal of Surgical Oncology|October 28, 2015
Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanomaDevin C Flaherty, Brianna W Hoffner, Briana J Lau, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 27, 2018
Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?Constantin A Dasanu, Yazeed Samara, Ion Codreanu, et al.
Cancer Immunology, Immunotherapy : CII|March 3, 2012
Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumabVafa Shahabi, Gena Whitney, Omid Hamid, et al.
American Journal of Clinical Oncology|January 24, 2015
Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanomaLynn E Spitler, Peter Boasberg, Steven O'Day, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2012
Sunitinib therapy for melanoma patients with KIT mutationsDavid R Minor, Mohammed Kashani-Sabet, Maria Garrido, et al.
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Programmed death 1 immune checkpoint inhibitorsMeghna S Trivedi, Brianna Hoffner, Jennifer L Winkelmann, et al.
Journal of Translational Medicine|April 19, 2018
The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017Paolo A Ascierto, Corrado Caracò, Jeffrey E Gershenwald, et al.
Frontiers in Medicine|December 26, 2022
Case report: Later onset of NRAS-mutant metastatic melanoma in a patient with a partially-excised giant congenital melanocytic nevusBruno Almeida Costa, Victor Zibara, Vasundhara Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk diseaseOmid Hamid, Jolie C Solomon, Ronald Scotland, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanomaJeffrey S Weber, Omid Hamid, Scott D Chasalow, et al.
Pageof 19